Pan-Asia Catalysts/Events, Quiddity Advisors

David Blennerhassett

Pan-Asia Catalysts/Events

Quiddity Advisors

Event-Driven

<ul>
<li>Shareholders have given <strong><a href="https://www.smartkarma.com/entities/sciclone-pharmaceuticals-holdings-limited" target="_blank" data-smartkarma-citation="entities:17351:1" rel="noopener">SciClone Pharmaceuticals (6600 HK)</a></strong>'s buyback the go-ahead which will result in the major shareholder holding (upward of) 31.63%, and the freedom to creep.</li>
<li>As such, a concentrated shareholder register, primarily comprising entities that privatised SciClone in 2017, gets even more concentrated.</li>
<li>Trading inexpensively ahead of the launch of a new (and approved) drug, SciClone is worth a second look. </li>
</ul>


Shareholders have given SciClone Pharmaceuticals (6600 HK)'s buyback the go-ahead which will result in the major shareholder holding (upward of) 31.63%, and the freedom to creep.
As such, a concentrated shareholder register, primarily comprising entities that privatised SciClone in 2017, gets even more concentrated.
Trading inexpensively ahead of the launch of a new (and approved) drug, SciClone is worth a second look. 


SciClone Pharma (6600 HK): Inexpensive Ahead Of New Therapies Rolling Out

HK/China Healthcare Analyst (ex-Fosun Pharma)

Xinyao (Criss) Wang

Equity Bottom-Up

SciClone Pharmaceuticals / Equity Bottom-Up

<ul>
<li>Zadaxin has been the biggest performance driver of SciClone, but it would face the risk of losing market share and increased pricing pressures after generic drugs were included in VBP.</li>
<li>SciClone is primarily a pharmaceutical development/sales company, rather than a research-based innovative drug company.The increasingly low cost performance of in-licensed products has made the capital “reconsider” and be more rational.</li>
<li>SciClone is a good stock for short-term trade, especially by taking advantage of the positive momentum after it reaches licensing deals/launches new products, but we're concerned about its long-term prospects.</li>
</ul>


Zadaxin has been the biggest performance driver of SciClone, but it would face the risk of losing market share and increased pricing pressures after generic drugs were included in VBP.
SciClone is primarily a pharmaceutical development/sales company, rather than a research-based innovative drug company.The increasingly low cost performance of in-licensed products has made the capital “reconsider” and be more rational.
SciClone is a good stock for short-term trade, especially by taking advantage of the positive momentum after it reaches licensing deals/launches new products, but we're concerned about its long-term prospects.


Sciclone Pharmaceuticals (6600.HK) - The Business, the Outlook and the Challenges

Asia Pac ECM and Index Rebal, Shenton Research

Ke Yan, CFA, FRM

Asia Pac ECM and Index Rebal

Asia Pac IPO & Placement Research, China Biotech

DZT Research

DZT Research is an independent Asia Pacific equity specialist. Our quantitative research covers index rebalancing flows, alongside exchange data analytics accross Asia Pacific. On the equity capital markets side, we focus on Asia Pacific ECM, especially biotech and TMT. Our lead analyst is frequently cited by international media.

Quantitative Analysis

<ul>
<li>We analyze the weekly Hong Kong Connect flows with our data engine for holding position as of January 13th.</li>
<li>The top stocks by inflows and outflows were tabulated for all market, HSCEI, mid cap and s/mid cap groups.</li>
<li>We highlight flows for China Mobile, Simcere Pharmaceutical, Tencent, Geely Automobile.</li>
</ul>


We analyze the weekly Hong Kong Connect flows with our data engine for holding position as of January 13th.
The top stocks by inflows and outflows were tabulated for all market, HSCEI, mid cap and s/mid cap groups.
We highlight flows for China Mobile, Simcere Pharmaceutical, Tencent, Geely Automobile.


Hong Kong Connect Flows (Jan 13th): Tencent Profit Taking

<ul>
<li>We analyze the weekly Hong Kong Connect flows with our data engine for holding position as of January 6th.</li>
<li>The top stocks by inflows and outflows were tabulated for all market, HSCEI, mid cap and s/mid cap groups.</li>
<li>We highlight flows for Tencent, China Mobile, Wuxi Biologics, Kuaishou Technology.</li>
</ul>


We analyze the weekly Hong Kong Connect flows with our data engine for holding position as of January 6th.
The top stocks by inflows and outflows were tabulated for all market, HSCEI, mid cap and s/mid cap groups.
We highlight flows for Tencent, China Mobile, Wuxi Biologics, Kuaishou Technology.


Hong Kong Connect Flows (Jan 6th): Tencent, China Mobile, Wuxi Biologics, Kuaishou

<ul>
<li>We analyze the monthly Hong Kong Connect flows with our data engine.</li>
<li>We tabulate the top stocks by inflows, outlfows, and holding by mainland investors.</li>
<li>We highlight inflows into Meituan, HKEX, China Unicom, Shenzhou Intl, Sensetime, and outflows from Xiaomi, HSBC, Anta Sports, China Pacific.</li>
</ul>


We analyze the monthly Hong Kong Connect flows with our data engine.
We tabulate the top stocks by inflows, outlfows, and holding by mainland investors.
We highlight inflows into Meituan, HKEX, China Unicom, Shenzhou Intl, Sensetime, and outflows from Xiaomi, HSBC, Anta Sports, China Pacific.


Hong Kong Connect Flows Monthly: 12 Months of Inflows

China

SciClone Pharmaceuticals is a biopharmaceutical company focused on developing and commercializing pharmaceutical products for oncology and severe infection in Mainland China and internationally. Its portfolio includes proprietary product Zadaxin, used for hepatitis B, hepatitis C, and certain cancers, as well as in-licensed products like Zometa, DANYELZA, and Angiomax. The company was founded in 1990 and is headquartered in Shanghai, China.

Price Gauge
52-week Range	0.00 - 0.00
Market Cap (USDm)	0.00
P/E	0.00
Dividend (Yield)	0.00

SciClone Pharmaceuticals (SCICLONE HK)

SciClone Pharma (6600 HK): Inexpensive Ahead Of New Therapies Rolling Out

It would not be surprising if the consortium which privatised SciClone six years ago, opts to do the same again. Or instigate an alternative...

David Blennerhassett

Sciclone Pharmaceuticals (6600.HK) - The Business, the Outlook and the Challenges

VBP/generic drugs are major obstacles to Zadaxin's sustained high growth in long term. SciClone is a good stock to trade in short term,but we've...

Xinyao (Criss) Wang

Hong Kong Connect Flows (Jan 13th): Tencent Profit Taking

We analyzed southbound Hong Kong connect flows in the past week and highlight flows for China Mobile, Simcere Pharmaceutical, Tencent, Geely...

Ke Yan, CFA, FRM

Hong Kong Connect Flows (Jan 6th): Tencent, China Mobile, Wuxi Biologics, Kuaishou

We analyzed southbound Hong Kong connect flows in the past week and highlight flows for Tencent, China Mobile, Wuxi Biologics, Kuaishou.

Ke Yan, CFA, FRM

Hong Kong Connect Flows Monthly: 12 Months of Inflows

We analyzed the Hong Kong Connect Scheme for December and highlight flows for Meituan, HKEX, China Unicom, Shenzhou Intl, Sensetime, Xiaomi, HSBC,...

Ke Yan, CFA, FRM

Price Gauge

52-week Range

Market Cap (USDm)

P/E

Dividend (Yield)